Back

Predictors of worsening kidney function and their relation to SGLT2 inhibitor dapagliflozin administration in type 2 diabetes mellitus patients with chronic heart failure

25 April 2024 (09:00 - 12:30)
Organised by: Logo
Congress Presentation Part of: Managing risk in the cardio-renal continuum Biomarkers Open Access ESC Preventive Cardiology 2024 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Professor Alexander E Berezin

Paracelsus Private Medical University, Salzburg (Austria)

5 More presentations in this session

Presentation thumbnail
Acute cardiorenal syndrome: baseline comorbidities, biomarkers and prognostic significance
Doctor G. Aletras (Heraklion, GR)
Abstract Slides
Presentation thumbnail
Estimation of renal functional reserve in patients with preserved renal function and coronary microvascular dysfunction
Doctor M. Bora (Athens, GR) Doctor A. Sakalidis (Athens, GR)
Abstract Slides
Presentation thumbnail
Association between urinary concentrations of heavy metals and trace elements and renal function in Swiss adults: a cross-sectional study
Miss S. Xie (Lausanne, CH)
Abstract Slides
Presentation thumbnail
Effects of cardiac rehabilitation on the renal function in patients aged 75 years and older with moderate to severe renal dysfunction.
Doctor T. Hama (Hachioji, JP)
Abstract Slides
Presentation thumbnail
Does endothelial function differ among sexes in patients with diabetes or kidney disease?
Ms M. Renier (Leuven, BE)
Abstract Slides

Access the full session

Session thumbnail
Managing risk in the cardio-renal continuum

The Event

Event poster

ESC Preventive Cardiology 2024

25 April - 27 April 2024
You may be interested in
thumbnail
Congress Presentation
The role of a multimarker panel in the diagnosis and prognosis of patients with acute heart failure
thumbnail
Congress Presentation
Novel biomarkers reveal distinct biological phenotypes in heart failure with preserved vs reduced ejection fraction
thumbnail
Congress Presentation
Growth differentiation factor 15 and absorption loss as new biomarkers of heart failure decompensation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources